Trial of Lu-177 DOTATATE (Lutathera®) in Unlicensed Indications

NCT06121271 · clinicaltrials.gov ↗

PHASE2

Phase

NOT_YET_RECRUITING

Status

110

Enrollment

OTHER

Sponsor class

Conditions

Bronchial and Thymic Neuroendocrine Tumour
Paraganglioma/ Phaeochromocytoma
Medullary Thyroid Carcinoma
Those Requiring Repeat Peptide Receptor Radionuclide Therapy

Interventions

DRUG: Lu-177 DOTATATE (Lutathera®)

Sponsor

University College, London